Table 1 Baseline characteristic of study patients
Variable | All (n = 30) | Placebo (n = 15) | Dapagliflozin (n = 15) | p |
|---|---|---|---|---|
Age, years | 63.4 ± 6.9 | 61.0 ± 7.2 | 65.7 ± 5.9 | 0.057 |
Sex male, % | 66.7 | 66.7 | 66.7 | 1.000 |
Body mass index, kg/m2 | 30.8 ± 5.2 | 32.8 ± 5.4 | 28.8 ± 4.3 | 0.032§ |
HbA1c, % | 8.2 ± 0.8 | 8.2 ± 0.9 | 8.2 ± 0.6 | 0.981 |
Diabetes duration, years | 14.1 ± 6.6 | 13.9 ± 5.2 | 14.2 ± 8.0 | 0.914 |
Hypertension, % | 90.0 | 93.3 | 86.7 | 1.000 |
Smoking habit, % | 16.7 | 20.0 | 13.3 | 1.000 |
Dyslipidemia, % | 93.3 | 86.7 | 100 | 0.483 |
Creatinine, mg/dl | 0.81 ± 0.2 | 0.81 ± 0.2 | 0.82 ± 0.2 | 0.921 |
eGFR (ml/min/1.73 m2) | 90.6 ± 16.7 | 92.5 ± 16.9 | 88.7 ± 17.0 | 0.551 |
Retinopathy, % | 26.7 | 33.3 | 20.0 | 0.682 |
Nephropathy, % | 23.3 | 33.3 | 13.3 | 0.390 |
Neuropathy, % | 3.3 | 6.7 | 0.0 | 1.000 |
Coronary artery disease, % | 26.7 | 40.0 | 13.3 | 0.215 |
History of HF or systolic LV dysfunction, % | 0.0 | 0.0 | 0.0 | 1.000 |
LV hypertrophy, % | 46.7 | 53.3 | 40.0 | 0.715 |
Diastolic LV disfunction, % | 43.3 | 46.7 | 40.0 | 1.000 |
Peripheral arterial disease, % | 0.0 | 0.0 | 0.0 | 1.000 |
Cerebrovascular disease, % | 56.7 | 53.3 | 60.0 | 1.000 |
Metformin, % | 93.3 | 100 | 86.7 | 0.483 |
Sulphonylureas, % | 20.0 | 20.0 | 20.0 | 1.000 |
DPP-4 inhibitors, % | 20.0 | 13.3 | 26.7 | 0.651 |
Basal insulin, % | 16.7 | 13.3 | 20.0 | 1.000 |
Basal-bolus insulin, % | 36.7 | 46.7 | 26.7 | 0.500 |
ACE inhibitors/ARBs, % | 83.3 | 86.7 | 80.0 | 1.000 |
Diuretics, % | 33.3 | 26.7 | 40.0 | 0.700 |
Calcium channel blockers, % | 30.0 | 33.3 | 26.7 | 1.000 |
Beta blocker, % | 26.7 | 26.7 | 26.7 | 1.000 |
Statins, % | 90.0 | 100.0 | 80.0 | 0.224 |
Anti-platelets, % | 50.0 | 60.0 | 40.0 | 0.466 |